BioWorld - Monday, December 16, 2019

Analysis and data insight
%{topic} RSS Feed RSS

Edwards Lifesciences Sapien 3

Edwards keeps momentum going with earnings beat, as TAVR sales grow more than 25%

October 25, 2019
By Stacy Lawrence
No Comments
Edwards Lifesciences Corp. has been unstoppable so far this year, driven by the rapidly expanding adoption of transcatheter heart valve therapy. It beat expectations in its third-quarter earnings report, drawing praise and even higher expectations from Wall Street analysts. The Irvine, Calif.-based company recently received an expanded FDA indication for its Sapien 3 and Sapien 3 Ultra TAVR systems to treat surgical low-risk patients with severe aortic stenosis. (See BioWorld MedTech, Aug. 19, 2019.)
Read More
stocks-compass.png

Boston Sci climbs 6% on earnings beat, but still down since next-gen TAVR results at TCT

October 24, 2019
By Stacy Lawrence
No Comments
A relief rebound drove Boston Scientific Corp. up 6% on positive third-quarter earnings news. But that wasn't enough to recover all the ground that shares (NYSE:BSX) of the Marlborough, Mass.-based medical device giant lost last month on the disappointing next-generation transcatheter aortic valve replacement (TAVR) study results presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference held last month in San Francisco.
Read More
AI-tech-head.png
2019 Medical Innovations Summit

Panel discusses critical gaps in AI in health care

October 23, 2019
By Liz Hollis
No Comments
CLEVELAND – What are some of the biggest challenges related using to artificial intelligence (AI) in health care? A panel of experts tackled that question during a session Tuesday during the 2019 Medical Innovations Summit, while also discussing what their organizations have done in this space to advance patient care.
Read More

Enthusiasm for biopharmas focused on cancer medicines muted

October 21, 2019
By Peter Winter
No Comments
While the general markets are leaning toward positive territory following a quiet summer period, the enthusiasm for biopharma equities remains muted. One of the most closely monitored therapeutic areas is oncology. Earlier this year, public companies developing innovative medicines in that area had enjoyed strong support; however, investors now appear to be more selective in backing companies in that sector.
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe